Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 12/2003

01-12-2003 | Observation

Mechanism underlying resistance of human pancreatic beta cells against toxicity of streptozotocin and alloxan

Authors: M. Elsner, M. Tiedge, S. Lenzen

Published in: Diabetologia | Issue 12/2003

Login to get access

Excerpt

To the Editor: The diabetogenic agents, streptozotocin and alloxan induce insulin deficiency due to their selective pancreatic beta-cell toxicity [1]. However, there are significant species differences in the diabetogenicity of streptozotocin and alloxan [1]. While rodents are particularly prone to the diabetogenic action of these two diabetogens, humans are considered to be resistant [1]. Human pancreatic beta cells, in contrast to rodent beta cells, have been shown to be resistant to the toxic action of streptozotocin and alloxan in vitro [2, 3, 4]. …
Literature
1.
Rerup CC (1970) Drugs producing diabetes through damage of the insulin secreting cells. Pharmacol Rev 22: 485–518PubMed
2.
Eizirik DL, Pipeleers DG, Ling Z, Welsh N, Hellerstrom C, Andersson A (1994) Major species differences between humans and rodents in the susceptibility to pancreatic beta-cell injury. Proc Natl Acad Sci USA 91: 9253–9256PubMed
3.
Tyrberg B, Andersson A, Borg LA (2001) Species differences in susceptibility of transplanted and cultured pancreatic islets to the beta-cell toxin alloxan. Gen Comp Endocrinol 122: 238–251CrossRefPubMed
4.
Yang H, Wright JR (2002) Human beta cells are exceedingly resistant to streptozotocin in vivo. Endocrinology 143: 2491–2495PubMed
5.
Elsner M, Guldbakke B, Tiedge M, Munday R, Lenzen S (2000) Relative importance of transport and alkylation for pancreatic beta-cell toxicity of streptozotocin. Diabetologia 43: 1528–1533
6.
Elsner M, Tiedge M, Guldbakke B, Munday R, Lenzen S (2002) Importance of the GLUT2 glucose transporter for pancreatic beta-cell toxicity of alloxan. Diabetologia 45: 1542–1549CrossRefPubMed
7.
De Vos A, Heimberg H, Quartier E, Huypens P, Bouwens L, Pipeleers D, Schuit F (1995) Human and rat beta cells differ in glucose transporter but not in glucokinase gene expression. J Clin Invest 96: 2489–2495PubMed
8.
Ferrer J, Benito C, Gomis R (1995) Pancreatic islet GLUT2 glucose transporter mRNA and protein expression in humans with and without NIDDM. Diabetes 44: 1369–1374PubMed
9.
Welsh N, Margulis B, Borg LA, Wiklund HJ, Saldeen J, Flodstrom M, Mello MA, Andersson A, Pipeleers DG, Hellerstrom C, Eizirik DL (1995) Differences in the expression of heat-shock proteins and antioxidant enzymes between human and rodent pancreatic islets: implications for the pathogenesis of insulin-dependent diabetes mellitus. Mol Med 1: 806–820PubMed
10.
Tiedge M, Lortz S, Drinkgern J, Lenzen S (1997) Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells. Diabetes 46: 1733–1742PubMed
11.
Grankvist K, Lernmark A, Täljedal IB (1979) Trypan Blue as a marker of plasma membrane permeability in alloxan-treated mouse islet cells. J Endocrinol Invest 2: 139–145PubMed
12.
Wilson GL, Patton NJ, McCord JM, Mullins DW, Mossman BT (1984) Mechanisms of streptozotocin- and alloxan-induced damage in rat B cells. Diabetologia 27: 587–591PubMed
Metadata
Title
Mechanism underlying resistance of human pancreatic beta cells against toxicity of streptozotocin and alloxan
Authors
M. Elsner
M. Tiedge
S. Lenzen
Publication date
01-12-2003
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 12/2003
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-003-1241-2

Other articles of this Issue 12/2003

Diabetologia 12/2003 Go to the issue

Review

Regulation of adipocytokines and insulin resistance

Article

Rosiglitazone produces insulin sensitisation by increasing expression of the insulin receptor and its tyrosine kinase activity in brown adipocytes

Observation

Absence of association between SPINK1 trypsin inhibitor mutations and Type 1 or 2 diabetes mellitus in India and Germany

Article

Long-term overexpression of glucokinase in the liver of transgenic mice leads to insulin resistance

Article

Change in patients’ body weight after 12 months of treatment with glimepiride or glibenclamide in Type 2 diabetes: a multicentre retrolective cohort study

Short Communication

Effects of recurrent antecedent hypoglycaemia and chronic hyperglycaemia on brainstem extra-cellular glucose concentrations during acute hypoglycaemia in conscious diabetic BB rats
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits